SEC Form S-1 filed by Health Sciences Acquisitions Corporation 2
$HSAQ
Medical/Dental Instruments
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
5 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
3 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
3 - Orchestra BioMed Holdings, Inc. (0001814114) (Reporting)
8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The combination was announced simultaneously with Orchestra's strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients Gross proceeds from transaction and previously completed financing led by RTW and Medtronic total approximately $180 million and support cash runway into 2026 Orchestra BioMed Holdings, Inc. to commence trading on January 27 on Nasdaq Global Market under ticker symbol "OBIO"
NEW HOPE, Pa., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc., ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies, today announced the presentation of positive long-term clinical results from the MODERATO II Control Patients Crossover Extension Study of BackBeat Cardiac Neuromodulation Therapy™ ("BackBeat CNT") at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 annual conference being held in Boston, MA. BackBeat CNT is a bioelectronic therapy candidate that is compatible with standard pacemakers and designed to lower bloo
Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients Investors in $110 million Series D financing include Medtronic and Terumo as well as lead investor RTW Investments and founding investor Perceptive Advisors Business combination with Health Sciences Acquisitions Corporation 2 (NASDAQ:HSAQ) (the "Business Combination"); upon closing, the common stock of the combined company is expected to be listed on Nasdaq under the ticker symbol "OBIO"; Business Combination is supported by $20 million in total forward purchase agreements and an up to $50 million backstop agreement
SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
SC 13G - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)